Outcome of patients with Hodgkin's disease failing after primary MOPP- ABVD

V. Bonfante, A. Santoro, S. Viviani, L. Devizzi, M. Balzarotti, F. Soncini, M. Zanini, P. Valagussa, G. Bonadonna

Research output: Contribution to journalArticle

Abstract

Purpose: This study analyzed long-term results in patients with Hodgkin's disease who were resistant to or relapsed after first-line treatment with MOPP and ABVD. Response to salvage treatments and prognostic factors were also evaluated. Patients and Methods: The study population included 115 refractory or relapsed patients among a total of 415 patients treated with alternating or hybrid MOPP-ABVD followed by radiotherapy (25 to 30 Gy) to initial bulky sites. The median follow-up duration of the present series was 91 months. Thirty-nine of 115 patients (34%) showed disease progression while on primary treatment (induction failures); 48 relapsed after complete remissions that lasted ≤ 12 months and 28 after complete remission that lasted more than 12 months from the end of all treatments. Results: At 8 years, the overall survival rate was 27%, being 54% and 28% in patients whose initial complete remission was longer or shorter than 12 months, respectively, and 8% in induction failures (P <.001). Response to first-line chemotherapy and disease extent at first progression significantly influenced long-term results, as well as the incidence and duration of complete remission. Conclusion: The present data confirm previous observations that showed the main prognostic factors to influence outcome after salvage treatment are response duration to first-line therapy and disease extent at relapse. The results indicate that patients who relapse after the alternating MOPP/ABVD regimen have a prognosis similar to that of patients who relapse after a four-drug regimen (MOPP or ABVD alone). Re- treatment with initial chemotherapy seems the treatment of choice for patients who relapse after an initial complete remission that lasts greater than 12 months, while the real impact of high-dose chemotherapy or new regimens should be assessed in resistant patients.

Original languageEnglish
Pages (from-to)528-534
Number of pages7
JournalJournal of Clinical Oncology
Volume15
Issue number2
Publication statusPublished - Feb 1997

Fingerprint

Hodgkin Disease
Recurrence
Salvage Therapy
Drug Therapy
Therapeutics
Treatment Failure
Disease Progression
Radiotherapy
Survival Rate
Incidence

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Outcome of patients with Hodgkin's disease failing after primary MOPP- ABVD. / Bonfante, V.; Santoro, A.; Viviani, S.; Devizzi, L.; Balzarotti, M.; Soncini, F.; Zanini, M.; Valagussa, P.; Bonadonna, G.

In: Journal of Clinical Oncology, Vol. 15, No. 2, 02.1997, p. 528-534.

Research output: Contribution to journalArticle

Bonfante, V, Santoro, A, Viviani, S, Devizzi, L, Balzarotti, M, Soncini, F, Zanini, M, Valagussa, P & Bonadonna, G 1997, 'Outcome of patients with Hodgkin's disease failing after primary MOPP- ABVD', Journal of Clinical Oncology, vol. 15, no. 2, pp. 528-534.
Bonfante, V. ; Santoro, A. ; Viviani, S. ; Devizzi, L. ; Balzarotti, M. ; Soncini, F. ; Zanini, M. ; Valagussa, P. ; Bonadonna, G. / Outcome of patients with Hodgkin's disease failing after primary MOPP- ABVD. In: Journal of Clinical Oncology. 1997 ; Vol. 15, No. 2. pp. 528-534.
@article{d1037296e75246aa987eb3a8f2489812,
title = "Outcome of patients with Hodgkin's disease failing after primary MOPP- ABVD",
abstract = "Purpose: This study analyzed long-term results in patients with Hodgkin's disease who were resistant to or relapsed after first-line treatment with MOPP and ABVD. Response to salvage treatments and prognostic factors were also evaluated. Patients and Methods: The study population included 115 refractory or relapsed patients among a total of 415 patients treated with alternating or hybrid MOPP-ABVD followed by radiotherapy (25 to 30 Gy) to initial bulky sites. The median follow-up duration of the present series was 91 months. Thirty-nine of 115 patients (34{\%}) showed disease progression while on primary treatment (induction failures); 48 relapsed after complete remissions that lasted ≤ 12 months and 28 after complete remission that lasted more than 12 months from the end of all treatments. Results: At 8 years, the overall survival rate was 27{\%}, being 54{\%} and 28{\%} in patients whose initial complete remission was longer or shorter than 12 months, respectively, and 8{\%} in induction failures (P <.001). Response to first-line chemotherapy and disease extent at first progression significantly influenced long-term results, as well as the incidence and duration of complete remission. Conclusion: The present data confirm previous observations that showed the main prognostic factors to influence outcome after salvage treatment are response duration to first-line therapy and disease extent at relapse. The results indicate that patients who relapse after the alternating MOPP/ABVD regimen have a prognosis similar to that of patients who relapse after a four-drug regimen (MOPP or ABVD alone). Re- treatment with initial chemotherapy seems the treatment of choice for patients who relapse after an initial complete remission that lasts greater than 12 months, while the real impact of high-dose chemotherapy or new regimens should be assessed in resistant patients.",
author = "V. Bonfante and A. Santoro and S. Viviani and L. Devizzi and M. Balzarotti and F. Soncini and M. Zanini and P. Valagussa and G. Bonadonna",
year = "1997",
month = "2",
language = "English",
volume = "15",
pages = "528--534",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "2",

}

TY - JOUR

T1 - Outcome of patients with Hodgkin's disease failing after primary MOPP- ABVD

AU - Bonfante, V.

AU - Santoro, A.

AU - Viviani, S.

AU - Devizzi, L.

AU - Balzarotti, M.

AU - Soncini, F.

AU - Zanini, M.

AU - Valagussa, P.

AU - Bonadonna, G.

PY - 1997/2

Y1 - 1997/2

N2 - Purpose: This study analyzed long-term results in patients with Hodgkin's disease who were resistant to or relapsed after first-line treatment with MOPP and ABVD. Response to salvage treatments and prognostic factors were also evaluated. Patients and Methods: The study population included 115 refractory or relapsed patients among a total of 415 patients treated with alternating or hybrid MOPP-ABVD followed by radiotherapy (25 to 30 Gy) to initial bulky sites. The median follow-up duration of the present series was 91 months. Thirty-nine of 115 patients (34%) showed disease progression while on primary treatment (induction failures); 48 relapsed after complete remissions that lasted ≤ 12 months and 28 after complete remission that lasted more than 12 months from the end of all treatments. Results: At 8 years, the overall survival rate was 27%, being 54% and 28% in patients whose initial complete remission was longer or shorter than 12 months, respectively, and 8% in induction failures (P <.001). Response to first-line chemotherapy and disease extent at first progression significantly influenced long-term results, as well as the incidence and duration of complete remission. Conclusion: The present data confirm previous observations that showed the main prognostic factors to influence outcome after salvage treatment are response duration to first-line therapy and disease extent at relapse. The results indicate that patients who relapse after the alternating MOPP/ABVD regimen have a prognosis similar to that of patients who relapse after a four-drug regimen (MOPP or ABVD alone). Re- treatment with initial chemotherapy seems the treatment of choice for patients who relapse after an initial complete remission that lasts greater than 12 months, while the real impact of high-dose chemotherapy or new regimens should be assessed in resistant patients.

AB - Purpose: This study analyzed long-term results in patients with Hodgkin's disease who were resistant to or relapsed after first-line treatment with MOPP and ABVD. Response to salvage treatments and prognostic factors were also evaluated. Patients and Methods: The study population included 115 refractory or relapsed patients among a total of 415 patients treated with alternating or hybrid MOPP-ABVD followed by radiotherapy (25 to 30 Gy) to initial bulky sites. The median follow-up duration of the present series was 91 months. Thirty-nine of 115 patients (34%) showed disease progression while on primary treatment (induction failures); 48 relapsed after complete remissions that lasted ≤ 12 months and 28 after complete remission that lasted more than 12 months from the end of all treatments. Results: At 8 years, the overall survival rate was 27%, being 54% and 28% in patients whose initial complete remission was longer or shorter than 12 months, respectively, and 8% in induction failures (P <.001). Response to first-line chemotherapy and disease extent at first progression significantly influenced long-term results, as well as the incidence and duration of complete remission. Conclusion: The present data confirm previous observations that showed the main prognostic factors to influence outcome after salvage treatment are response duration to first-line therapy and disease extent at relapse. The results indicate that patients who relapse after the alternating MOPP/ABVD regimen have a prognosis similar to that of patients who relapse after a four-drug regimen (MOPP or ABVD alone). Re- treatment with initial chemotherapy seems the treatment of choice for patients who relapse after an initial complete remission that lasts greater than 12 months, while the real impact of high-dose chemotherapy or new regimens should be assessed in resistant patients.

UR - http://www.scopus.com/inward/record.url?scp=0031033626&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031033626&partnerID=8YFLogxK

M3 - Article

C2 - 9053474

AN - SCOPUS:0031033626

VL - 15

SP - 528

EP - 534

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 2

ER -